CUMULATIVE SUPPLEMENT 1
JANUARY 2017



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

Cumulative Supplement 1
January 2017

CONTENTS

PAGE

1.0 INTRODUCTION v
1.1 How to use the Cumulative Supplement v
1.2 Cumulative Supplement Content vi
1.3 Applicant Name Changes vii
1.4 Levothyroxine Sodium vii
1.5 Availability of the Edition viii
1.6 Report of Counts for the Prescription Drug Product List ix
1.7 Cumulative Supplement Legend x

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act
Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Product Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability
Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

CUMULATIVE SUPPLEMENT 1
January 2017

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharmas NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2016	MAR 2017	JUN 2017	SEP 2017	DEC 2017
DRUG PRODUCTS	18130				
LISTED SINGLE SOURCE	2646 (14.6%)				
MULTISOURCE	15484 (85.4%)				
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)				
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)				
EXCEPTIONS[1]	73 (0.4%)				
NEW MOLECULAR ENTITIES APPROVED	7				
NUMBER OF APPLICANTS	1051				

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change

addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:
The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book(EOB)query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

>A>	AP		CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan CAHN
>D>	AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

PERCOCET

>A>	AA	!	VINTAGE PHARMS LLC	325MG;7.5MG	A040330	003	Nov 23, 2001	Jan CMS1
>A>	AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Jan CMS1

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>A>		@	CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997	Jan CAHN
>D>		@	DAVA PHARMS INC	200MG	A074872	001	Apr 22, 1997	Jan CAHN

ZOVIRAX

>D>	AB	+	DELCOR ASSET CORP	200MG	N018828	001	Jan 25, 1985	Jan CAHN
>A>	AB	+!	MYLAN PHARMS INC	200MG	N018828	001	Jan 25, 1985	Jan CAHN

SUSPENSION;ORAL

ZOVIRAX

>D>	AB	+	DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jan CAHN
>A>	AB	+!	MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan CAHN

TABLET;ORAL

ACYCLOVIR

>A>		@	CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997	Jan CAHN
>A>		@		800MG	A074834	002	Apr 24, 1997	Jan CAHN
>D>		@	DAVA PHARMS INC	400MG	A074834	001	Apr 24, 1997	Jan CAHN
>D>		@		800MG	A074834	002	Apr 24, 1997	Jan CAHN

ZOVIRAX

>D>	AB		DELCOR ASSET CORP	400MG	N020089	001	Apr 30, 1991	Jan CAHN
>D>	AB	+		800MG	N020089	002	Apr 30, 1991	Jan CAHN
>A>	AB	+	MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan CAHN
>A>	AB	+!		800MG	N020089	002	Apr 30, 1991	Jan CAHN

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

>D>	AP		EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Jan CAHN
>D>	AP			3MG/ML	A076500	001	Jun 16, 2004	Jan CAHN
>D>		@		3MG/ML	A076501	001	Jun 16, 2004	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan CAHN
>A>	AP			3MG/ML	A076500	001	Jun 16, 2004	Jan CAHN
>A>		@		3MG/ML	A076501	001	Jun 16, 2004	Jan CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

>A>	AB		AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
>A>	AB			1MG	A090871	002	Jun 07, 2011	Jan CAHN
>A>	AB			2MG	A090871	003	Jun 07, 2011	Jan CAHN
>A>	AB			3MG	A090871	004	Jun 07, 2011	Jan CAHN
>D>	AB		AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
>D>	AB			1MG	A090871	002	Jun 07, 2011	Jan CAHN
>D>	AB			2MG	A090871	003	Jun 07, 2011	Jan CAHN
>D>	AB			3MG	A090871	004	Jun 07, 2011	Jan CAHN

AMANTADINE HYDROCHLORIDE

SYRUP;ORAL

SYMMETREL

>D>		@	ENDO PHARMS	50MG/5ML	N016023	002		Jan CRLD
>A>		+ @		50MG/5ML	N016023	002		Jan CRLD

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

>A>	AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan NEWA

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

>A>	AB		MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan CAHN
>D>	AB		SWAN PHARMS LLC	200MG	A075389	001	Jan 25, 2001	Jan CAHN

CORDARONE

>D>	AB	+!	WYETH PHARMS INC	200MG	N018972	001	Dec 24, 1985	Jan DISC
>A>		+ @		200MG	N018972	001	Dec 24, 1985	Jan DISC

AMMONIUM LACTATE

LOTION;TOPICAL

LAC-HYDRIN

>D>		@	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
>A>		+ @		EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>D>		@	EUROHLTH INTL SARL	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan CAHN
>D>		@		EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan CAHN
>D>		@		EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan CAHN
>D>		@		EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan CAHN
>D>		@		EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan CAHN
>D>		@		EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan CAHN
>A>		@	WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan CAHN
>A>		@		EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan CAHN
>A>		@		EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan CAHN
>A>		@		EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan CAHN
>A>		@		EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan CAHN
>A>		@		EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>D>	AP		EUROHLTH INTL SARL	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
>D>	AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN
>D>	AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
>A>	AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN
>A>	AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORINAL

>D>		@	ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CRLD
>A>		+ @		325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CRLD

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

>A>	AB		IMPAX LABS INC	25MG;200MG	A206964	001	Jan 18, 2017	Jan NEWA
>A>	AB		PAR PHARM INC	25MG;200MG	A207944	001	Jan 18, 2017	Jan NEWA
>A>	AB		SANDOZ INC	25MG;200MG	A206739	001	Jan 18, 2017	Jan NEWA

AZITHROMYCIN

INJECTABLE;INJECTION

AZITHROMYCIN

>A>	AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB	!	FOUGERA	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan CAHN
>A>	AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan CAHN

DIPROSONE

>D>		@	SCHERING	EQ 0.05% BASE	N017781	001		Jan CRLD
>A>		+ @		EQ 0.05% BASE	N017781	001		Jan CRLD

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

LUXIQ

>D>	AB	+	DELCOR ASSET CORP	0.12%	N020934	001	Feb 28, 1999	Jan	CAHN
>A>	AB	+!	MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan	CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

>A>		@	IMPAX LABS	5MG	A040721	001	Nov 01, 2006	Jan	CMS1
>A>		@		10MG	A040721	002	Nov 01, 2006	Jan	CMS1
>A>		@		25MG	A040721	003	Nov 01, 2016	Jan	CMS1

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

>A>	AB		ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan	NEWA
>A>	AB			10MG	A204891	002	Jan 11, 2017	Jan	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ZIAC

>A>	AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan	CAHN
>A>	AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Jan	CAHN
>A>	AB	+!		10MG;6.25MG	N020186	002	Mar 26, 1993	Jan	CAHN
>D>	AB	+	TEVA WOMENS	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan	CAHN
>D>	AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Jan	CAHN
>D>	AB	+!		10MG;6.25MG	N020186	002	Mar 26, 1993	Jan	CAHN

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

>D>		@	EUROHLTH INTL SARL	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN
>A>		@	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

>D>	AP		EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN
>A>	AP		WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

>A>		+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CAHN
>A>		+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CAHN
>A>		+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CAHN
>A>		+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CAHN
>A>		+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CAHN
>A>		+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CAHN
>A>		+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CAHN
>D>			ENDO PHARMS INC	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CAHN
>D>				EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CAHN
>D>				EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CAHN
>D>				EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CAHN
>D>				EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CAHN
>D>				EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CAHN
>D>		+		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

ZUBSOLV

>D>		+!	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan	CHRS
>A>		+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan	CHRS
>D>		+		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan	CHRS
>A>		+!		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan	CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FORFIVO XL

>A>		+!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN
>D>		+!	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011	Jan CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

>D>	AP		EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
>D>	AP			2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
>A>	AP			2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

>A>		+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan CAHN
>D>		+	STIEFEL LABS INC	0.005%	N022563	001	Oct 06, 2010	Jan CAHN

CARBAMAZEPINE

SOLUTION;IV (INFUSION)

CARNEXIV

>D>		+!	LUNDBECK LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan CAHN
>A>		+!	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan CAHN

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

>A>	AP		ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan NEWA
>A>	AP			150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan NEWA
>A>	AP			450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan NEWA
>A>	AP			600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan NEWA
>A>	AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan NEWA
>A>	AP			150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan NEWA
>A>	AP			450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan NEWA
>A>	AP			600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan NEWA

CEFDINIR

CAPSULE;ORAL

OMNICEF

>D>		@	ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan CRLD
>A>		+ @		300MG	N050739	001	Dec 04, 1997	Jan CRLD

FOR SUSPENSION;ORAL

OMNICEF

>D>		@	ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan CRLD
>A>		+ @		125MG/5ML	N050749	001	Dec 04, 1997	Jan CRLD
>D>		@		250MG/5ML	N050749	002	Jul 29, 2004	Jan CRLD
>A>		+ @		250MG/5ML	N050749	002	Jul 29, 2004	Jan CRLD

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

>A>	AB		BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan NEWA
>A>	AB			200MG/5ML	A206938	002	Feb 06, 2017	Jan NEWA
>A>	AB			500MG/5ML	A206939	001	Feb 06, 2017	Jan NEWA

SUPRAX

>D>		+!	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG
>A>	AB	+!		500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG

CEFOXITIN SODIUM

INJECTABLE;INJECTION

CEFOXITIN

>D>	AP		EUROHLTH INTL SARL	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
>D>	AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
>D>	AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
>A>	AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
>A>	AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN

CEFPROZIL

TABLET;ORAL

CEFPROZIL

>D>	AB		AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
>A>	AB			250MG	A065340	001	May 24, 2007	Jan CAHN
>D>	AB			500MG	A065340	002	May 24, 2007	Jan CAHN
>A>	AB			500MG	A065340	002	May 24, 2007	Jan CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE SODIUM

>A>	AP		SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

>D>		@	HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
>A>		+ @		EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
>D>		@		EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
>A>		+ @		EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
>D>		@		EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD
>A>		+ @		EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

>D>	AB		AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
>A>	AB			EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
>D>	AB			EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
>A>	AB			EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
>D>	AB			EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN
>A>	AB			EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

>D>	AB		AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
>A>	AB			EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
>D>	AB			EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN
>A>	AB			EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION

CEPHAPIRIN SODIUM

>D>		@	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
>D>		@		EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
>D>		@		EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
>D>		@		EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN
>A>		@	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
>A>		@		EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
>A>		@		EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
>A>		@		EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>D>		+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Jan CAHN
>A>		!	WEST-WARD PHARMS INT	25MG/ML	A083329	001		Jan CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

>A>		@	ANI PHARMS INC	250MG	A087353	001		Jan CAHN
>D>		@	TEVA PHARMS USA	250MG	A087353	001		Jan CAHN

CILOSTAZOL

TABLET;ORAL

PLETAL

>D>		@	OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan CRLD
>A>		+ @		50MG	N020863	001	Jan 15, 1999	Jan CRLD
>D>		@		100MG	N020863	002	Jan 15, 1999	Jan CRLD
>A>		+ @		100MG	N020863	002	Jan 15, 1999	Jan CRLD

CIMETIDINE

TABLET;ORAL

CIMETIDINE

>A>		@ CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan CAHN
>A>		@	300MG	A074281	002	May 17, 1994	Jan CAHN
>A>		@	400MG	A074281	003	May 17, 1994	Jan CAHN
>A>		@	800MG	A074329	001	May 17, 1994	Jan CAHN
>D>		@ VINTAGE PHARMS LLC	200MG	A074281	001	May 17, 1994	Jan CAHN
>D>		@	300MG	A074281	002	May 17, 1994	Jan CAHN
>D>		@	400MG	A074281	003	May 17, 1994	Jan CAHN
>D>		@	800MG	A074329	001	May 17, 1994	Jan CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

>A>	AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

>D>	AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan CAHN
>A>	AA		EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

>D>	AT	+ DELCOR ASSET CORP	1%	N050801	001	Oct 22, 2004	Jan CAHN
>A>	AT	+! MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

>D>	AP	EUROHLTH INTL SARL	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	AT	FOUGERA	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
>A>	AT	FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN

CLOBAZAM

SUSPENSION;ORAL

ONFI

>D>		+! LUNDBECK LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN
>A>		+! LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN

TABLET;ORAL

ONFI

>D>		@ LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
>D>		+	10MG	N202067	002	Oct 21, 2011	Jan CAHN
>D>		+!	20MG	N202067	003	Oct 21, 2011	Jan CAHN
>A>		@ LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
>A>		+	10MG	N202067	002	Oct 21, 2011	Jan CAHN
>A>		+!	20MG	N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

OLUX

>D>	AB1	+ DELCOR ASSET CORP	0.05%	N021142	001	May 26, 2000	Jan CAHN
>A>	AB1	+! MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan CAHN

OLUX E

>D>	AB2	+ DELCOR ASSET	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
>A>	AB2	+! MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN

CREAM;TOPICAL

CLOBETASOL PROPIONATE

>D>	AB1	FOUGERA	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
>A>	AB1	FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
>A>		@ MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	Jan CAHN
>D>		@ RENAISSANCE PHARMA	0.05%	A075338	001	Feb 09, 2001	Jan CAHN

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

>A>		@ MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	Jan CAHN
>D>		@ RENAISSANCE PHARMA	0.05%	A075057	001	Aug 12, 1998	Jan CAHN

		OINTMENT;TOPICAL						
		TEMOVATE						
>D>		@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD
>A>		+ @	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD
		CLOPIDOGREL BISULFATE						
		TABLET;ORAL						
		CLOPIDOGREL BISULFATE						
>A>	AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan	NEWA
		CODEINE SULFATE						
		SOLUTION;ORAL						
		CODEINE SULFATE						
>D>		@ ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan	CAHN
>A>		@ WEST-WARD PHARMS INT	30MG/5ML	N202245	001	Jun 30, 2011	Jan	CAHN
		TABLET;ORAL						
		CODEINE SULFATE						
>D>	AB	+ ROXANE	15MG	N022402	001	Jul 16, 2009	Jan	CAHN
>D>	AB	+	30MG	N022402	002	Jul 16, 2009	Jan	CAHN
>D>	AB	+!	60MG	N022402	003	Jul 16, 2009	Jan	CAHN
>A>	AB	+ WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan	CAHN
>A>	AB	+	30MG	N022402	002	Jul 16, 2009	Jan	CAHN
>A>	AB	+!	60MG	N022402	003	Jul 16, 2009	Jan	CAHN
		CYCLOPHOSPHAMIDE						
		CAPSULE;ORAL						
		CYCLOPHOSPHAMIDE						
>D>		ROXANE	25MG	N203856	001	Sep 16, 2013	Jan	CAHN
>D>		+	50MG	N203856	002	Sep 16, 2013	Jan	CAHN
>A>		+ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan	CAHN
>A>		+!	50MG	N203856	002	Sep 16, 2013	Jan	CAHN
		CYPROHEPTADINE HYDROCHLORIDE						
		SYRUP;ORAL						
		PERIACTIN						
>D>		@ MERCK	2MG/5ML	N013220	002		Jan	CRLD
>A>		+ @	2MG/5ML	N013220	002		Jan	CRLD
		TABLET;ORAL						
		CYPROHEPTADINE HYDROCHLORIDE						
>A>	AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan	NEWA
		DALFAMPRIDINE						
		TABLET, EXTENDED RELEASE;ORAL						
		AMPYRA						
>D>		+! ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
>A>	AB	+!	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
>A>		DALFAMPRIDINE						
>A>	AB	ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan	NEWA
>A>	AB	AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan	NEWA
		DESOXIMETASONE						
		GEL;TOPICAL						
		TOPICORT						
>D>		@ TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD
>A>		+ @	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD
		SPRAY;TOPICAL						
>A>		DESOXIMETASONE						
>A>	AT	PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan	NEWA
		TOPICORT						
>D>		+ TARO	0.25%	N204141	001	Apr 11, 2013	Jan	CFTG
>A>	AT	+!	0.25%	N204141	001	Apr 11, 2013	Jan	CFTG
		DICLOFENAC SODIUM; MISOPROSTOL						
		TABLET, DELAYED RELEASE;ORAL						
		DICLOFENAC SODIUM AND MISOPROSTOL						
>A>	AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan	CAHN
>A>	AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan	CAHN
>D>	AB	EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan	CAHN
>D>	AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan	CAHN

DIGOXIN

ELIXIR;ORAL

DIGOXIN

>D>		+	ROXANE	0.05MG/ML	N021648	001	Aug 26, 2004	Jan CAHN
>A>		+!	WEST-WARD PHARMS INT	0.05MG/ML	N021648	001	Aug 26, 2004	Jan CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

>D>	AP		EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Jan CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

>D>	AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Jan CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

>A>	AB		CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan CAHN
>A>	AB			500MG	A091563	002	Dec 31, 2012	Jan CAHN
>D>	AB		VINTAGE PHARMS	250MG	A091563	001	Dec 31, 2012	Jan CAHN
>D>	AB			500MG	A091563	002	Dec 31, 2012	Jan CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

>A>	AP		DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan NEWA
>A>	AP			80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan NEWA
>A>				200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan NEWA
>A>		+	HOSPIRA INC	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan NEWA
>A>		!	JIANGSU HENGRUI MED	40MG/ML	A203170	001	Feb 15, 2017	Jan NEWA
>D>			PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan DISC
>A>		@		20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan DISC
>D>				80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan DISC
>A>		@		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan DISC
>D>				130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan DISC
>A>		@		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan DISC
>D>				200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan DISC
>A>		@		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

>A> MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

>A>	AB		AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan NEWA
>A>	AB			10MG;28MG	A208328	002	Jan 27, 2017	Jan NEWA

NAMZARIC

>D>		+	FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan CFTG
>A>	AB	+		10MG;14MG	N206439	001	Dec 23, 2014	Jan CFTG
>D>		+!		10MG;28MG	N206439	002	Dec 23, 2014	Jan CFTG
>A>	AB	+!		10MG;28MG	N206439	002	Dec 23, 2014	Jan CFTG

DOXEPIN HYDROCHLORIDE

CREAM;TOPICAL

ZONALON

>D>		+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Jan CAHN
>A>		+!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

VIBRAMYCIN

>D>		@	PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan CRLD
>A>		+ @		EQ 100MG BASE/VIAL	N050442	002		Jan CRLD
>D>		@		EQ 200MG BASE/VIAL	N050442	001		Jan CRLD
>A>		+ @		EQ 200MG BASE/VIAL	N050442	001		Jan CRLD

TABLET;ORAL

DOXYCYCLINE HYCLATE

>D>		@	BLU CARIBE INC	EQ 50MG BASE	A062269	003		Jan CAHN
>D>	AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan CAHN

		TABLET;ORAL						
		DOXYCYCLINE HYCLATE						
>A>		@ CARIBE HOLDINGS	EQ 50MG BASE	A062269	003			Jan CAHN
>A>	AB		EQ 100MG BASE	A062269	002	Nov 08, 1982		Jan CAHN
		EPHEDRINE SULFATE						
		SOLUTION;IV (INFUSION)						
>A>		CORPHEDRA						
>A>		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017		Jan NEWA
		EPLERENONE						
		TABLET;ORAL						
		EPLERENONE						
>A>	AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017		Jan NEWA
>A>	AB		50MG	A203896	002	Feb 02, 2017		Jan NEWA
		ERYTHROMYCIN						
		GEL;TOPICAL						
		E-GLADES						
>A>		@ MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002		Jan CAHN
>D>		@ RENAISSANCE PHARMA	2%	A065009	001	Mar 18, 2002		Jan CAHN
		ERYGEL						
>D>	AT +	DELCOR ASSET CORP	2%	N050617	001	Oct 21, 1987		Jan CAHN
>A>	AT +!	MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987		Jan CAHN
		SWAB;TOPICAL						
		ERYTHROMYCIN						
>A>		@ MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996		Jan CAHN
>D>		@ RENAISSANCE PHARMA	2%	A064128	001	Jul 03, 1996		Jan CAHN
		ESTRADIOL; NORETHINDRONE ACETATE						
		TABLET;ORAL						
		ESTRADIOL AND NORETHINDRONE ACETATE						
>A>	AB	MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017		Jan NEWA
>A>	AB		1MG;0.5MG	A207261	002	Feb 10, 2017		Jan NEWA
		ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE						
		TABLET;ORAL-28						
		ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL						
>A>	AB	JAI PHARMA LTD	0.035MG;1MG	A204703	001	Jul 28, 2016		Jan NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE						
		TABLET, CHEWABLE;ORAL						
>A>		NEXESTA FE						
>A>	AB	AUROBINDO PHARMA LTD	0.035MG;0.4MG	A207535	001	Feb 02, 2017		Jan NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE						
		TABLET;ORAL						
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
>A>	AB	MYLAN LABS LTD	0.0025MG;0.5MG	A207260	001	Feb 02, 2017		Jan NEWA
		ETODOLAC						
		CAPSULE;ORAL						
		ETODOLAC						
>A>		@ CHARTWELL PHARMS LLC	200MG	A074842	001	Jul 17, 1997		Jan CAHN
>A>		@	300MG	A074842	002	Jul 17, 1997		Jan CAHN
>D>		@ VINTAGE PHARMS LLC	200MG	A074842	001	Jul 17, 1997		Jan CAHN
>D>		@	300MG	A074842	002	Jul 17, 1997		Jan CAHN
		TABLET;ORAL						
		ETODOLAC						
>A>		@ CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997		Jan CAHN
>D>		@ VINTAGE PHARMS LLC	400MG	A074841	001	Jun 27, 1997		Jan CAHN
		ETOMIDATE						
		INJECTABLE;INJECTION						
		ETOMIDATE						
>D>	AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996		Jan CAHN
>A>	AP	MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017		Jan NEWA
>A>	AP	WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996		Jan CAHN

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

>D>	AB		TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan CHRS
>A>	AB	!		500MG	A077487	003	Aug 24, 2007	Jan CHRS

FAMVIR

>D>	AB	+	NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan DISC
>A>		+ @		125MG	N020363	003	Dec 11, 1995	Jan DISC
>D>	AB	+		250MG	N020363	001	Apr 26, 1996	Jan DISC
>A>		+ @		250MG	N020363	001	Apr 26, 1996	Jan DISC
>D>	AB	+!		500MG	N020363	002	Jun 29, 1994	Jan DISC
>A>		+ @		500MG	N020363	002	Jun 29, 1994	Jan DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

>D>	AB		AUROBINDO PHARM	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
>D>	AB			200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN
>A>	AB		AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
>A>	AB			200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

>D>			EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
>D>	AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
>D>	AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN
>A>			WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
>A>	AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
>A>	AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP		EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
>D>	AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
>A>	AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

>D>	AP		EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
>D>	AP			0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
>D>	AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
>D>	AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
>A>	AP			0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
>A>	AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
>A>	AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

>D>	AT		FOUGERA	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
>D>	AT			0.025%	A088169	001	Dec 16, 1982	Jan CAHN
>A>	AT		FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
>A>	AT			0.025%	A088169	001	Dec 16, 1982	Jan CAHN

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

>D>	AT		FOUGERA	0.025%	A088168	001	Dec 16, 1982	Jan CAHN
>A>	AT		FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan CAHN

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

>D>	AT		FOUGERA	0.01%	A088167	001	Dec 16, 1982	Jan CAHN
>A>	AT		FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan CAHN

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

>D>	AB1		FOUGERA	0.05%	A073030	001	Oct 17, 1994	Jan CAHN
>A>	AB1		FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan CAHN

GEL;TOPICAL

FLUOCINONIDE

>D>	AB		FOUGERA	0.05%	A072933	001	Dec 30, 1994	Jan CAHN
>A>	AB		FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan CAHN

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

>D>		@	SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CRLD
>A>		+ @		500MG/10ML (50MG/ML)	N012209	001		Jan CRLD

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AA		AUROBINDO PHARM	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan CAHN
>A>	AA		AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

>A>		+!	ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan CAHN
>D>		+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

>A>		@	ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan CAHN
>D>		@	TEVA PHARMS	5MG/ML	A073058	001	Aug 30, 1991	Jan CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

>A>		@	AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991	Jan CMS1

FLUTICASONE PROPIONATE

POWDER;INHALATION

>A> ARMONAIR RESPICLICK

>A>		+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan NEWA
>A>		+		0.113MG/INH	N208798	002	Jan 27, 2017	Jan NEWA
>A>		+!		0.232MG/INH	N208798	003	Jan 27, 2017	Jan NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

>A> AIRDUO RESPICLICK

>A>		+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan NEWA
>A>		+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan NEWA
>A>		+!		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan NEWA

FOSINOPRIL SODIUM

TABLET;ORAL

MONOPRIL

>D>		@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan CRLD
>A>		+ @		10MG	N019915	002	May 16, 1991	Jan CRLD
>D>		@		20MG	N019915	003	May 16, 1991	Jan CRLD
>A>		+ @		20MG	N019915	003	May 16, 1991	Jan CRLD
>D>		@		40MG	N019915	004	Mar 28, 1995	Jan CRLD
>A>		+ @		40MG	N019915	004	Mar 28, 1995	Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

>D>	AP		EUROHLTH INTL SARL	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan CAHN
>D>	AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan CAHN
>A>	AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan CAHN

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

>D>	AB		ROXANE	20MG	N018823	001	Nov 10, 1983	Jan CAHN
>D>	AB			40MG	N018823	002	Nov 10, 1983	Jan CAHN
>A>	AB		WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan CAHN
>A>	AB			40MG	N018823	002	Nov 10, 1983	Jan CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>D>	AB	AUROBINDO PHARM	100MG	A078787	001	Jan 31, 2008	Jan CAHN
>D>	AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
>D>	AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
>A>	AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
>A>	AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
>A>	AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

>D>	AB	BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Jan CAHN
>A>	AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan CAHN

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

>D>	AT	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan CHRS
>A>	AT	!	EQ 0.1% BASE	A062307	001		Jan CHRS
>D>	AT	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC
>A>		@	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC

OINTMENT;TOPICAL

GENTAMICIN SULFATE

>D>	AT	FOUGERA	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN
>A>	AT	FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

METAGLIP

>D>		@ BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan CRLD
>A>		+ @	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan CRLD
>D>		@	2.5MG;500MG	N021460	002	Oct 21, 2002	Jan CRLD
>A>		+ @	2.5MG;500MG	N021460	002	Oct 21, 2002	Jan CRLD
>D>		@	5MG;500MG	N021460	003	Oct 21, 2002	Jan CRLD
>A>		+ @	5MG;500MG	N021460	003	Oct 21, 2002	Jan CRLD

GLYCOPYRROLATE

POWDER;INHALATION

SEEBRI

>D>		+! NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan CAHN
>A>		+! SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON

>D>		+! NOVARTIS PHARMS CORP	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	Jan CAHN
>A>		+! SUNOVION PHARMS INC	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	Jan CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

CHORIONIC GONADOTROPIN

>D>		@ FERRING	5,000 UNITS/VIAL	N017016	006		Jan CMFD
>A>		+!	5,000 UNITS/VIAL	N017016	006		Jan CMFD

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan CAHN
>A>	AP	MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan NEWA
>A>	AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>A>	AP		GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>A>	AA		NOVEL LABS INC	1.5MG/5ML;5MG/5ML	A203535	001	Feb 13, 2017	Jan NEWA
>A>	AA		PADDOCK LLC	1.5MG/5ML;5MG/5ML	A205731	001	Feb 15, 2017	Jan NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

PRINZIDE

>D>		@	MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan CRLD
>A>		+ @		12.5MG;10MG	N019778	003	Nov 18, 1993	Jan CRLD
>D>		@		12.5MG;20MG	N019778	001	Feb 16, 1989	Jan CRLD
>A>		+ @		12.5MG;20MG	N019778	001	Feb 16, 1989	Jan CRLD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB		HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
>A>	AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Jan CMS1
>A>	AB			25MG;15MG	A202150	003	Mar 07, 2014	Jan CMS1

MOEXIPRIL HYDROCHLORIDE AND HYDROCHOLROTHIAZIDE

>D>	AB		HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
>D>	AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Jan CMS1
>D>	AB			25MG;15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

>A>								
>A>		+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan NEWA
>A>		+		30MG	N207975	002	Jan 17, 2017	Jan NEWA
>A>		+		45MG	N207975	003	Jan 17, 2017	Jan NEWA
>A>		+		60MG	N207975	004	Jan 17, 2017	Jan NEWA
>A>		+		90MG	N207975	005	Jan 17, 2017	Jan NEWA

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

>D>	AT	!	FOUGERA	1%	A080693	003		Jan CAHN
>D>	AT	!		2.5%	A089414	001	Dec 16, 1986	Jan CAHN
>A>	AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan CAHN
>A>	AT	!		2.5%	A089414	001	Dec 16, 1986	Jan CAHN

OINTMENT;TOPICAL

HYDROCORTISONE

>D>	AT	!	FOUGERA	2.5%	A081203	001	May 28, 1993	Jan CAHN
>A>	AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

>A>	AP	+!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
>A>	AP	+!		2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
>A>	AP	+!		4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN
>D>	AP	+!	PURDUE PHARM PRODS	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
>D>	AP	+!		2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
>D>	AP	+!		4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN

DILAUDID-HP

>A>	AP	+!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
>A>		@		250MG/VIAL	N019034	002	Aug 04, 1994	Jan CAHN
>D>	AP	+!	PURDUE PHARM PRODS	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
>D>		@		250MG/VIAL	N019034	002	Aug 04, 1994	Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

VISTARIL

>D>		@ PFIZER	25MG/ML	N011111	001			Jan CRLD
>A>	+	@	25MG/ML	N011111	001			Jan CRLD
>D>		@	50MG/ML	N011111	002			Jan CRLD
>A>	+	@	50MG/ML	N011111	002			Jan CRLD

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

>A>		@ AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982		Jan CMS1
>A>		@	25MG	A087871	003	Dec 20, 1982		Jan CMS1

IBUPROFEN

SUSPENSION;ORAL

MOTRIN

>D>		@ MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989		Jan CRLD
>A>	+	@	100MG/5ML	N019842	001	Sep 19, 1989		Jan CRLD

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

>D>	+!	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011		Jan CAHN
>A>	+!	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011		Jan CAHN

IOPAMIDOL

INJECTABLE;INJECTION

SCANLUX-300

>D>	AP	MYLAN INSTITUTIONAL	61%	A090394	001	Jun 18, 2010		Jan CAHN
>A>	AP	MYLAN IRELAND LTD	61%	A090394	001	Jun 18, 2010		Jan CAHN

SCANLUX-370

>D>	AP	MYLAN INSTITUTIONAL	76%	A090394	002	Jun 18, 2010		Jan CAHN
>A>	AP	MYLAN IRELAND LTD	76%	A090394	002	Jun 18, 2010		Jan CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008		Jan CAHN
>D>	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008		Jan CAHN
>A>	AP	WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008		Jan CAHN
>A>	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008		Jan CAHN

KANAMYCIN SULFATE

INJECTABLE;INJECTION

KANAMYCIN

>D>		@ EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001			Jan CAHN
>D>		@	EQ 500MG BASE/2ML	A062324	002			Jan CAHN
>D>		@	EQ 1GM BASE/3ML	A062324	003			Jan CAHN
>A>		@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001			Jan CAHN
>A>		@	EQ 500MG BASE/2ML	A062324	002			Jan CAHN
>A>		@	EQ 1GM BASE/3ML	A062324	003			Jan CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

EXTINA

>D>	AT	+ DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007		Jan CAHN
>A>	AT	+! MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007		Jan CAHN

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>A>	AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013		Jan CAHN
>A>	AB		50MG	A202887	002	Jun 17, 2013		Jan CAHN
>A>	AB		100MG	A202887	003	Jun 17, 2013		Jan CAHN
>A>	AB		200MG	A202887	004	Jun 17, 2013		Jan CAHN
>D>	AB	WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013		Jan CAHN
>D>	AB		50MG	A202887	002	Jun 17, 2013		Jan CAHN
>D>	AB		100MG	A202887	003	Jun 17, 2013		Jan CAHN
>D>	AB		200MG	A202887	004	Jun 17, 2013		Jan CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>	AN		AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan NEWA

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

>D>	AA		AUROBINDO PHARM	100MG/ML	A079063	001	Jan 15, 2009	Jan CAHN
>A>	AA		AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>		@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
>A>		+ @		EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
>D>		@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
>A>		+ @		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
>D>		@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD
>A>		+ @		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

>A>	AP		ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
>A>	AP		AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

>D>	AT	!	FOUGERA	5%	A080198	001		Jan CAHN
>A>	AT	!	FOUGERA PHARMS INC	5%	A080198	001		Jan CAHN

XYLOCAINE

>D>		@	ASTRAZENECA	5%	N008048	001		Jan CRLD
>A>		+ @		5%	N008048	001		Jan CRLD

LINACLOTIDE

CAPSULE;ORAL

LINZESS

>A>		+	FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan NEWA

LISDEXAMFETAMINE DIMESYLATE

>A> TABLET, CHEWABLE;ORAL

>A> VYVANSE

>A>		+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan NEWA
>A>		+		20MG	N208510	002	Jan 28, 2017	Jan NEWA
>A>		+		30MG	N208510	003	Jan 28, 2017	Jan NEWA
>A>		+		40MG	N208510	004	Jan 28, 2017	Jan NEWA
>A>		+		50MG	N208510	005	Jan 28, 2017	Jan NEWA
>A>		+		60MG	N208510	006	Jan 28, 2017	Jan NEWA

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

>D>	AB		DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Jan CAHN
>D>	AB			300MG	A076243	001	Jun 27, 2002	Jan CAHN
>D>	AB			600MG	A078763	001	Apr 15, 2008	Jan CAHN
>A>	AB		MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan CAHN
>A>	AB			300MG	A076243	001	Jun 27, 2002	Jan CAHN
>A>	AB			600MG	A078763	001	Apr 15, 2008	Jan CAHN
>D>	AB		ROXANE	150MG	N017812	002	Jan 28, 1987	Jan CAHN
>D>	AB			300MG	N017812	001		Jan CAHN
>D>	AB	+		600MG	N017812	003	Jan 28, 1987	Jan CAHN
>A>	AB	+	WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan CAHN
>A>	AB	+		300MG	N017812	001		Jan CAHN
>A>	AB	+!		600MG	N017812	003	Jan 28, 1987	Jan CAHN

TABLET;ORAL

LITHIUM CARBONATE

>D>	AB	+	ROXANE	300MG	N018558	001	Jan 29, 1982	Jan CAHN
>A>	AB	+!	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

>D>	AA	+	ROXANE	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
>A>	AA	+!	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

>D>	AB		TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN
>A>	AB			150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

>D>	AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Jan CAHN
>D>	AP			25MG/ML	A080455	007		Jan CAHN
>D>	AP			50MG/ML	A080445	002		Jan CAHN
>D>	AP			50MG/ML	A080455	008		Jan CAHN
>D>	AP			75MG/ML	A080445	003		Jan CAHN
>D>	AP			75MG/ML	A080455	009		Jan CAHN
>D>	AP			100MG/ML	A080445	004		Jan CAHN
>D>	AP			100MG/ML	A080455	010		Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan CAHN
>A>	AP			25MG/ML	A080455	007		Jan CAHN
>A>	AP			50MG/ML	A080445	002		Jan CAHN
>A>	AP			50MG/ML	A080455	008		Jan CAHN
>A>	AP			75MG/ML	A080445	003		Jan CAHN
>A>	AP			75MG/ML	A080455	009		Jan CAHN
>A>	AP			100MG/ML	A080445	004		Jan CAHN
>A>	AP			100MG/ML	A080455	010		Jan CAHN

METHADONE HYDROCHLORIDE

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

>D>		@	ROXANE	10MG/30ML	N006134	004		Jan CAHN
>A>		@	WEST-WARD PHARMS INT	10MG/30ML	N006134	004		Jan CAHN

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

>D>	AA	+!	ROXANE	5MG	N006134	002		Jan CAHN
>D>	AA	+!		10MG	N006134	010		Jan CAHN
>A>	AA	+!	WEST-WARD PHARMS INT	5MG	N006134	002		Jan CAHN
>A>	AA	+!		10MG	N006134	010		Jan CAHN

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

>D>	AA	+!	ROXANE	40MG	N017058	001		Jan CAHN
>A>	AA	+!	WEST-WARD PHARMS INT	40MG	N017058	001		Jan CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

>A>	AP		RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan NEWA

TABLET;ORAL

METHOCARBAMOL

>A>	AA		ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan NEWA
>A>	AA			750MG	A203550	002	Feb 08, 2017	Jan NEWA

METHOTREXATE SODIUM

TABLET;ORAL

METHOTREXATE SODIUM

>A>	AB		ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan NEWA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

>D>	AP	!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC
>A>		!		50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB		NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
>A>	AB			5MG	A204954	002	Jan 26, 2017	Jan NEWA
>A>	AB			10MG	A204954	003	Jan 26, 2017	Jan NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

>D>	AP		HOSPIRA INC	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Jan DISC
>A>		@		EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Jan DISC
>D>	AP			EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Jan DISC
>A>		@		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Jan DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

TOPROL-XL

>A>	AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
>A>	AB	+!		EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
>A>	AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
>A>	AB	+!		EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN
>D>	AB	+	ASTRAZENECA PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
>D>	AB	+!		EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
>D>	AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
>D>	AB	+!		EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

>D>	AP		EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

>D>		+	DELCOR ASSET CORP	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
>A>		+!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
>D>	AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
>D>	AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
>D>	AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
>D>	AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
>D>	AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
>A>	AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
>A>	AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
>A>	AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
>A>	AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
>A>	AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

>D>	AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN
>D>	AP			EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN
>A>	AP			EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP		EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN
>D>	AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN
>A>	AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN

		INJECTABLE;INJECTION						
		PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>		@ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD	
>A>	+	@	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD	
>D>		@	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD	
>A>	+	@	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD	
>D>		@	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD	
>A>	+	@	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD	
>D>		@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD	
>A>	+	@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD	
		MIRTAZAPINE						
		TABLET, ORALLY DISINTEGRATING;ORAL						
		MIRTAZAPINE						
>D>	AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan CAHN	
>A>	AB		15MG	A077376	002	Dec 08, 2005	Jan CAHN	
>D>	AB		30MG	A077376	003	Dec 08, 2005	Jan CAHN	
>A>	AB		30MG	A077376	003	Dec 08, 2005	Jan CAHN	
>D>	AB		45MG	A077376	004	Feb 28, 2006	Jan CAHN	
>A>	AB		45MG	A077376	004	Feb 28, 2006	Jan CAHN	
		MITOMYCIN						
		INJECTABLE;INJECTION						
		MITOMYCIN						
>D>	AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Jan CAHN	
>D>	AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN	
>D>	AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan CAHN	
>D>	AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN	
>A>	AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan CAHN	
>A>	AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN	
>A>	AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan CAHN	
>A>	AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN	
		MUTAMYCIN						
>D>		@ BRISTOL	5MG/VIAL	N050450	001		Jan CRLD	
>A>	+	@	5MG/VIAL	N050450	001		Jan CRLD	
>D>		@	20MG/VIAL	N050450	002		Jan CRLD	
>A>	+	@	20MG/VIAL	N050450	002		Jan CRLD	
		MORPHINE SULFATE						
		SOLUTION;ORAL						
		MORPHINE SULFATE						
>D>	AA	+ ROXANE	10MG/5ML	N022195	001	Mar 17, 2008	Jan CAHN	
>D>	AA	+	20MG/5ML	N022195	002	Mar 17, 2008	Jan CAHN	
>D>	AA	+!	100MG/5ML	N022195	003	Jan 25, 2010	Jan CAHN	
>A>	AA	+ WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan CAHN	
>A>	AA	+	20MG/5ML	N022195	002	Mar 17, 2008	Jan CAHN	
>A>	AA	+!	100MG/5ML	N022195	003	Jan 25, 2010	Jan CAHN	
		TABLET;ORAL						
		MORPHINE SULFATE						
>D>		+ ROXANE	15MG	N022207	001	Mar 17, 2008	Jan CAHN	
>D>		+!	30MG	N022207	002	Mar 17, 2008	Jan CAHN	
>A>		+ WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan CAHN	
>A>		+!	30MG	N022207	002	Mar 17, 2008	Jan CAHN	
		TABLET, EXTENDED RELEASE;ORAL						
>A>		ARYMO ER						
>A>		+ EGALET	15MG	N208603	001	Jan 09, 2017	Jan NEWA	
>A>		+	30MG	N208603	002	Jan 09, 2017	Jan NEWA	
>A>		+	60MG	N208603	003	Jan 09, 2017	Jan NEWA	
>D>		MORPHABOND						
>D>		+ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan CTNA	
>D>		+	30MG	N206544	002	Oct 02, 2015	Jan CTNA	
>D>		+	60MG	N206544	003	Oct 02, 2015	Jan CTNA	
>D>		+!	100MG	N206544	004	Oct 02, 2015	Jan CTNA	
>A>		MORPHABOND ER						
>A>		+ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan CTNA	
>A>		+	30MG	N206544	002	Oct 02, 2015	Jan CTNA	
>A>		+	60MG	N206544	003	Oct 02, 2015	Jan CTNA	
>A>		+!	100MG	N206544	004	Oct 02, 2015	Jan CTNA	

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

>A>	AB		NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

>D>		@	EUROHLTH INTL SARL	0.4MG/ML	A070298	001	Sep 24, 1986	Jan CAHN
>D>		@		0.4MG/ML	A070496	001	Sep 24, 1986	Jan CAHN
>A>		@	WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986	Jan CAHN
>A>		@		0.4MG/ML	A070496	001	Sep 24, 1986	Jan CAHN

SPRAY, METERED;NASAL

NARCAN

>A>		+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

>A>	AB		AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan CAHN
>A>	AB			375MG	A200429	002	Nov 08, 2011	Jan CAHN
>A>	AB			500MG	A200429	003	Nov 08, 2011	Jan CAHN
>D>	AB		AUROBINDO PHARMA USA	250MG	A200429	001	Nov 08, 2011	Jan CAHN
>D>	AB			375MG	A200429	002	Nov 08, 2011	Jan CAHN
>D>	AB			500MG	A200429	003	Nov 08, 2011	Jan CAHN

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

>D>		+	ALCON	5%	N050514	001		Jan CAHN
>A>		+!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan CAHN

NELFINAVIR MESYLATE

POWDER;ORAL

VIRACEPT

>D>		@	AGOURON	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997	Jan CAHN
>A>		@	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997	Jan CAHN

TABLET;ORAL

VIRACEPT

>D>		+!	AGOURON	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan CAHN
>D>		+!		EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan CAHN
>A>		+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan CAHN
>A>		+!		EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan CAHN

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

>D>	AP		EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan CAHN

NITROGLYCERIN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

>D>		!	FOUGERA	2%	A087355	001	Jul 08, 1988	Jan CAHN
>A>		!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Jan CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

>D>	AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan CAHN

NYSTATIN

SUSPENSION;ORAL

NYSTATIN

>D>	AA		FOUGERA	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan CAHN
>A>	AA		FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCOLOG-II

>D>		@ DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan	CAHN
>A>		@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan	CAHN

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D>	AT	FOUGERA	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN
>A>	AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN

OINTMENT;TOPICAL

MYCOLOG-II

>D>		@ DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan	CAHN
>A>		@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan	CAHN

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A>	AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan	NEWA
>D>	AT	FOUGERA	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan	CAHN
>A>	AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan	CAHN

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

>A>	AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

>A>	AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan	CAHN
>A>	AB		20MG	A203270	002	Aug 19, 2015	Jan	CAHN
>A>	AB		40MG	A203270	003	Aug 19, 2015	Jan	CAHN
>D>	AB	AUROBINDO PHARMA USA	10MG	A203270	001	Aug 19, 2015	Jan	CAHN
>D>	AB		20MG	A203270	002	Aug 19, 2015	Jan	CAHN
>D>	AB		40MG	A203270	003	Aug 19, 2015	Jan	CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>D>	AA	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan	CTEC
>A>	AB		20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan	CTEC
>D>	AA		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan	CTEC
>A>	AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan	CTEC
>D>		@ PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan	CMFD
>A>	AB		20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan	CMFD
>D>		@	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan	CMFD
>A>	AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan	CMFD

ZEGERID

>D>	AA	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan	CTEC
>A>	AB +		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan	CTEC
>D>	AA +		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan	CTEC
>A>	AB +!		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan	CTEC

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan	CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN
>D>	AP		EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN
>A>	AP		EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

>D>		@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan	CRLD
>A>	+	@	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan	CRLD

OXALIPLATIN

>A>	AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan	NEWA
>A>	AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan	NEWA
>A>	AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan	NEWA
>A>	AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan	NEWA
>A>	AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan	NEWA

INJECTABLE;IV (INFUSION)
OXALIPLATIN

>A>	AP		GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan NEWA
>A>	AP			100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan NEWA
>D>		!	QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan CTEC
>A>	AP	!		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan CTEC

OXAZEPAM

TABLET;ORAL
OXAZEPAM

>D>			@ FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987	Jan CAHN
>A>			@ SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jan CAHN

OXYBUTYNIN CHLORIDE

SYRUP;ORAL
DITROPAN

>D>			@ ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001		Jan CRLD
>A>		+	@	5MG/5ML	N018211	001		Jan CRLD

OXYMETAZOLINE HYDROCHLORIDE

>A> CREAM;TOPICAL
>A> RHOFADE

>A>		+!	ALLERGAN INC	1%	N208552	001	Jan 18, 2017	Jan NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

>A>	AB		LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan NEWA
>A>	AB			EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan NEWA
>A>	AB			EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan NEWA

PENCICLOVIR

CREAM;TOPICAL
DENAVIR

>D>		+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Jan CAHN
>A>		+!	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
TRENTAL

>D>			@ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CRLD
>A>		+	@	400MG	N018631	001	Aug 30, 1984	Jan CRLD

PERMETHRIN

CREAM;TOPICAL
ELIMITE

>A>	AB	+!	MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989	Jan CAHN
>D>	AB	+	RENAISSANCE PHARMA	5%	N019855	001	Aug 25, 1989	Jan CAHN

PERPHENAZINE

TABLET;ORAL
PERPHENAZINE

>A>			@ ANI PHARMS INC	4MG	A089708	001	Sep 10, 1987	Jan CAHN
>D>			@ TEVA PHARMS USA	4MG	A089708	001	Sep 10, 1987	Jan CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

>A>	AB		PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Jan NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)
VAZCULEP

>A>		+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan CAHN
>A>		+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan CAHN
>A>		+!		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan CAHN
>D>		+	ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan CAHN
>D>		+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan CAHN
>D>		+!		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>A>	AP	APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan NEWA
>A>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan NEWA
>A>	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan NEWA
>A>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan NEWA

PIRFENIDONE

>A> TABLET;ORAL

>A> ESBRIET

>A>	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
>A>	+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
>A>	+!		801MG	N208780	003	Jan 11, 2017	Jan NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

>A>	AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan NEWA
>A>	AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan NEWA
>A>	AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan NEWA
>A>	AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan NEWA
>A>	AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan NEWA
>A>	AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan NEWA

>A> PLECANATIDE

>A> TABLET;ORAL

>A> TRULANCE

>A>	+!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
>A>		@	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
>D>	AB		0.25MG	A091254	002	Nov 30, 2010	Jan DISC
>A>		@	0.25MG	A091254	002	Nov 30, 2010	Jan DISC
>D>	AB		0.5MG	A091254	003	Nov 30, 2010	Jan DISC
>A>		@	0.5MG	A091254	003	Nov 30, 2010	Jan DISC
>D>	AB		0.75MG	A091254	004	Nov 30, 2010	Jan DISC
>A>		@	0.75MG	A091254	004	Nov 30, 2010	Jan DISC
>D>	AB		1MG	A091254	005	Nov 30, 2010	Jan DISC
>A>		@	1MG	A091254	005	Nov 30, 2010	Jan DISC
>D>	AB		1.5MG	A091254	006	Nov 30, 2010	Jan DISC
>A>		@	1.5MG	A091254	006	Nov 30, 2010	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A>	AB	AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
>A>	AB		20MG	A203367	002	Feb 02, 2017	Jan NEWA
>A>	AB		40MG	A203367	003	Feb 02, 2017	Jan NEWA
>A>	AB		80MG	A203367	004	Feb 02, 2017	Jan NEWA

PREDNISONE

TABLET;ORAL

PREDNISONE

>D>	AB	DELCOR ASSET CORP	5MG	A080292	001		Jan CAHN
>D>	AB		10MG	A088832	001	Dec 04, 1985	Jan CAHN
>D>	AB		20MG	A083677	001		Jan CAHN
>A>	AB	MYLAN PHARMS INC	5MG	A080292	001		Jan CAHN
>A>	AB		10MG	A088832	001	Dec 04, 1985	Jan CAHN
>A>	AB		20MG	A083677	001		Jan CAHN

PROBENECID

TABLET;ORAL

BENEMID

>D>		@ MERCK	500MG	N007898	004		Jan CRLD
>A>	+	@	500MG	N007898	004		Jan CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

>D>		@ EUROHLTH INTL SARL	100MG/ML	A089029	001	Apr 17, 1986	Jan CAHN
>A>		@ WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986	Jan CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

>D>		@ EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jan CAHN
>D>	AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jan CAHN
>A>		@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jan CAHN
>A>	AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PHENERGAN

>D>		@ DELCOR ASSET CORP	50MG	N011689	001		Jan CAHN
>A>	+	@ MYLAN PHARMS INC	50MG	N011689	001		Jan CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

LARGON

>D>		@ EUROHLTH INTL SARL	20MG/ML	N012382	002		Jan CAHN
>A>		@ WEST-WARD PHARMS INT	20MG/ML	N012382	002		Jan CAHN

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

INDERAL

>D>		@ WYETH PHARMS INC	40MG	N016418	002		Jan CRLD
>A>	+	@	40MG	N016418	002		Jan CRLD

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

>D>		@ EUROHLTH INTL SARL	10MG/ML	A089475	001	Nov 05, 1986	Jan CAHN
>A>		@ WEST-WARD PHARMS INT	10MG/ML	A089475	001	Nov 05, 1986	Jan CAHN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

>D>	AB	KREMERS URBAN DEV	20MG	A090678	001	Nov 08, 2013	Jan CAHN
>A>	AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

>D>	AP	+! IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
>A>	AP	+! TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA	AUROBINDO PHARM	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan CAHN
>A>	AA	AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan CAHN

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

>A>	AB	KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan CAHN
>D>	AB	THREE RIVERS PHARMS	200MG	A076203	001	Apr 06, 2004	Jan CAHN

TABLET;ORAL

RIBAVIRIN

>A>	AB	KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan CAHN
>A>	AB		400MG	A077456	002	Dec 05, 2005	Jan CAHN
>A>	AB	!	600MG	A077456	003	Dec 05, 2005	Jan CAHN
>D>	AB	THREE RIVERS PHARMS	200MG	A077456	001	Dec 05, 2005	Jan CAHN

TABLET;ORAL
RIBAVIRIN

>D> AB			400MG	A077456	002	Dec 05, 2005	Jan CAHN
>D> AB	!		600MG	A077456	003	Dec 05, 2005	Jan CAHN

RIFAMPIN
INJECTABLE;INJECTION
RIFAMPIN

>D> AP		EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Jan CAHN
>A> AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan CAHN

RIVASTIGMINE TARTRATE
CAPSULE;ORAL
RIVASTIGMINE TARTRATE

>A> AB		CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan NEWA
>A> AB			EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan NEWA
>A> AB			EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan NEWA
>A> AB			EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan NEWA

RIZATRIPTAN BENZOATE
TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

>A> AB		PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan NEWA
>A> AB			EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan NEWA

SELEGILINE HYDROCHLORIDE
TABLET;ORAL
SELEGILINE HYDROCHLORIDE

>A>	@	CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan CAHN
>A>	@		5MG	A074641	001	Aug 02, 1996	Jan CAHN
>D>	@	DAVA PHARMS INC	5MG	A074641	001	Aug 02, 1996	Jan CAHN
>D>	@	VINTAGE PHARMS LLC	5MG	A074565	001	Aug 02, 1996	Jan CAHN

SIMVASTATIN
SUSPENSION;ORAL
SIMVASTATIN

>D>		ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Jan CAHN
>D>	+		40MG/5ML	N206679	002	Apr 21, 2016	Jan CAHN
>A>	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan CAHN
>A>	+!		40MG/5ML	N206679	002	Apr 21, 2016	Jan CAHN

SODIUM CHLORIDE
INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

>D> AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN
>A> AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN

SODIUM CHLORIDE 0.9%

>D>		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN
>A>		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

>D>	@	ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD
>A>	+ @		234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD

SODIUM OXYBATE
SOLUTION;ORAL
>A> SODIUM OXYBATE

>A> AA		WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan NEWA

XYREM

>D>	+	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan CFTG
>A> AA	+!		500MG/ML	N021196	001	Jul 17, 2002	Jan CFTG

STERILE WATER FOR INJECTION
LIQUID;N/A
STERILE WATER FOR INJECTION

>D> AP		EUROHLTH INTL SARL	100%	A206369	001	Sep 02, 2015	Jan CAHN
>A> AP		WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	AB		CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Jan CAHN
>A>	AB			800MG;160MG	A078060	001	Jan 25, 2007	Jan CAHN
>D>	AB		VINTAGE	400MG;80MG	A078060	002	Jan 25, 2007	Jan CAHN
>D>	AB			800MG;160MG	A078060	001	Jan 25, 2007	Jan CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>D>	AP		EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan CAHN

>D> SYSTEM;IONTOPHORESIS

>D> ZECUITY

>D>		+!	TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan DISC
>A>		+ @		EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

>A>	AB		MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan NEWA

TAZAROTENE

AEROSOL, FOAM;TOPICAL

FABIOR

>A>		+!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan CAHN
>D>		+!	STIEFEL LABS INC	0.1%	N202428	001	May 11, 2012	Jan CAHN

TERBUTALINE SULFATE

TABLET;ORAL

TERBUTALINE SULFATE

>D>			LANNETT	5MG	A077152	002	Mar 25, 2005	Jan CHRS
>A>		!		5MG	A077152	002	Mar 25, 2005	Jan CHRS

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

>D>	AO		EUROHLTH INTL SARL	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
>D>	AO			200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN
>A>	AO		WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
>A>	AO			200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

>A>	AB		APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan NEWA
>A>	AB			25MG	A207682	002	Jan 31, 2017	Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

>A>	AB	+	HERITAGE PHARMA	250MG	N050278	003		Jan CAHN
>A>	AB	+!		500MG	N050278	001		Jan CAHN
>D>	AB		HERITAGE PHARMS INC	250MG	N050278	003		Jan CAHN
>D>	AB	+		500MG	N050278	001		Jan CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

>D>		@	EUROHLTH INTL SARL	100MG/ML	A080575	001		Jan CAHN
>A>		@	WEST-WARD PHARMS INT	100MG/ML	A080575	001		Jan CAHN

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

THIORIDAZINE HYDROCHLORIDE

>A>		@	ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987	Jan CAHN
>D>		@	TEVA PHARMS	30MG/ML	A089602	001	Nov 09, 1987	Jan CAHN

THIOTEPA

POWDER;IV (INFUSION)

TEPADINA

>A>		+!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan NEWA
>A>		+!		100MG/VIAL	N208264	002	Jan 26, 2017	Jan NEWA

TICAGRELOR

TABLET;ORAL

BRILINTA

>D>		+	ASTRAZENECA LP	60MG	N022433	002	Sep 03, 2015	Jan CAHN
>D>		+!		90MG	N022433	001	Jul 20, 2011	Jan CAHN
>A>		+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan CAHN
>A>		+!		90MG	N022433	001	Jul 20, 2011	Jan CAHN

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

>D>	AT		ALCON RES LTD	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Jan CHRS
>A>	AT	!		EQ 0.25% BASE	A074261	001	Apr 28, 1995	Jan CHRS
>D>	AT1			EQ 0.5% BASE	A074262	001	Apr 28, 1995	Jan CHRS
>A>	AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Jan CHRS

TIMOPTIC

>D>	AT	+	ATON	EQ 0.25% BASE	N018086	001		Jan DISC
>A>		+ @		EQ 0.25% BASE	N018086	001		Jan DISC
>D>	AT1	+		EQ 0.5% BASE	N018086	002		Jan DISC
>A>		+ @		EQ 0.5% BASE	N018086	002		Jan DISC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

>D>	BX		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
>A>	AB			250MG	A202489	001	Oct 09, 2013	Jan CTEC
>D>	BX			500MG	A202489	002	Oct 09, 2013	Jan CTEC
>A>	AB			500MG	A202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB		PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan NEWA
>A>	AB			EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan NEWA

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

>A>		+!	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
>D>		+!	PROSTRAKAN INC	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

>A>	AP		GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT		DELCOR ASSET CORP	0.025%	N011601	003		Jan CAHN
>D>	AT			0.1%	N011601	006		Jan CAHN
>A>	AT		LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan NEWA
>A>	AT			0.1%	A208763	002	Feb 01, 2017	Jan NEWA
>A>	AT			0.5%	A208763	003	Feb 01, 2017	Jan NEWA
>A>	AT	+	MYLAN PHARMS INC	0.025%	N011601	003		Jan CAHN
>A>	AT	+		0.1%	N011601	006		Jan CAHN

OINTMENT;TOPICAL

KENALOG

>D>	AT		DELCOR ASSET CORP	0.025%	N011600	003		Jan CAHN
>D>	AT			0.1%	N011600	001		Jan CAHN
>A>	AT		MYLAN PHARMS INC	0.025%	N011600	003		Jan CAHN
>A>	AT			0.1%	N011600	001		Jan CAHN

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

>A>	AT		G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan NEWA

SPRAY, METERED;NASAL
TRIAMCINOLONE ACETONIDE

>A>		@ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
>D>		@ TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN

ULIPRISTAL ACETATE
TABLET;ORAL
ELLA

>D>	+!	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
>A> AB	+!		30MG	N022474	001	Aug 13, 2010	Jan	CFTG

LOGILIA

>A> AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA

VECURONIUM BROMIDE
INJECTABLE;INJECTION
VECURONIUM BROMIDE

>D> AP		EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Jan	CAHN
>D> AP			20MG/VIAL	A075549	002	Jun 13, 2000	Jan	CAHN
>A> AP		WEST-WARD PHARMS INT	10MG/VIAL	A075549	001	Jun 13, 2000	Jan	CAHN
>A> AP			20MG/VIAL	A075549	002	Jun 13, 2000	Jan	CAHN

VERAPAMIL HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
CALAN SR

>D>		@ PFIZER	180MG	N019152	002	Dec 15, 1989	Jan	CRLD
>A>	+	@	180MG	N019152	002	Dec 15, 1989	Jan	CRLD

COVERA-HS

>D> BC	+	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan	DISC
>A>		@	180MG	N020552	001	Feb 26, 1996	Jan	DISC
>D> BC	+		240MG	N020552	002	Feb 26, 1996	Jan	DISC
>A>		@	240MG	N020552	002	Feb 26, 1996	Jan	DISC

VIGABATRIN
FOR SOLUTION;ORAL
SABRIL

>D>	+!	LUNDBECK LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Jan	CAHN
>A>	+!	LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Jan	CAHN

TABLET;ORAL
SABRIL

>D>	+!	LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009	Jan	CAHN
>A>	+!	LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan	CAHN

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

>D> AP		EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan	CAHN
>A> AP		WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan	CAHN

ZOLEDRONIC ACID
INJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

>A> AP		MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA

ZOLPIDEM TARTRATE
TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

>A> AB		SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
>A> AB			12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA

>A>	LEVOCETIRIZINE DIHYDROCHLORIDE						
>A>	SOLUTION;ORAL						
>A>	XYZAL ALLERGY 24HR						
>A>	+ UCB INC	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Jan	NEWA
>A>	TABLET;ORAL						
>A>	XYZAL ALLERGY 24HR						
>A>	+ UCB INC	5MG	N209089	001	Jan 31, 2017	Jan	NEWA
	LOPERAMIDE HYDROCHLORIDE						
>D>	TABLET, CHEWABLE;ORAL						
>D>	IMODIUM A-D EZ CHEWS						
>D>	+ J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997	Jan	DISC
>A>	+ @	2MG	N020448	001	Jul 24, 1997	Jan	DISC
	LOPERAMIDE HYDROCHLORIDE; SIMETHICONE						
	TABLET, CHEWABLE;ORAL						
>D>	IMODIUM MULTI-SYMPTOM RELIEF						
>D>	+ J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996	Jan	DISC
>A>	+ @	2MG;125MG	N020606	001	Jun 26, 1996	Jan	DISC
	LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE						
>D>	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002	Jan	CHRS
>A>	!	2MG;125MG	A076029	001	Aug 30, 2002	Jan	CHRS
	NAPROXEN SODIUM						
	TABLET;ORAL						
	NAPROXEN SODIUM						
>A>	LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017	Jan	NEWA
	RANITIDINE HYDROCHLORIDE						
	TABLET;ORAL						
	RANITIDINE HYDROCHLORIDE						
>A>	STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan	CAHN
>D>	SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan	CAHN
	TRIAMCINOLONE ACETONIDE						
	SPRAY, METERED;NASAL						
	TRIAMCINOLONE ACETONIDE						
>A>	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan	CAHN
>D>	TEVA PHARMS	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 01 JANUARY 2017

NO JANUARY 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JANUARY 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN - OFIRMEV						
N 022450 001					>A> M-196	Jan 27, 2020
					>A> PED	Jul 27, 2020
AFATINIB DIMALEATE - GILOTRIF						
N 201292 001	>A> 9539258	Nov 09, 2026	U-1950			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	>A> 9539258	Nov 09, 2026	U-1950			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 003	>A> 9539258	Nov 09, 2026	U-1950			
ALOGLIPTIN BENZOATE - NESINA						
N 022271 001	>A> 8173663	Dec 02, 2025	U-1338			
ALOGLIPTIN BENZOATE - NESINA						
N 022271 002	>A> 8173663	Dec 02, 2025	U-1338			
ALOGLIPTIN BENZOATE - NESINA						
N 022271 003	>A> 8173663	Dec 02, 2025	U-1338			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO						
N 203414 001	>A> 8288539	Jun 24, 2025	DS			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO						
N 203414 002	>A> 8288539	Jun 24, 2025	DS			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 005	>A> 6329404	Jun 19, 2021	DP U-1334			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	>A> 9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	>A> 9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	>A> 9526726	Mar 19, 2035	DP			
ASENAPINE MALEATE - SAPHRIS						
N 022117 001					>A> D-166	Jan 13, 2020
					>A> I-597	Jan 13, 2020
ASENAPINE MALEATE - SAPHRIS						
N 022117 002					>A> D-166	Jan 13, 2020
					>A> I-597	Jan 13, 2020
ASENAPINE MALEATE - SAPHRIS						
N 022117 003					>A> D-166	Jan 13, 2020
					>A> I-597	Jan 13, 2020
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 001	>A> 9539214	Mar 13, 2033	U-1902			
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 002	>A> 9539214	Mar 13, 2033	U-1902			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	001	>A> 9533955	Mar 26, 2029	DP U-1949			
		>A> 9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	002	>A> 9533955	Mar 26, 2029	DP U-1949			
		>A> 9533955	Mar 26, 2029	DP U-1952			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON							
N 050819	002	>A> 9561208	Jun 03, 2029	DP U-916			
BROMFENAC SODIUM - PROLENSA							
N 203168	001	>A> 9517220	Nov 11, 2033	U-1933			
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	>A> 9522117	Apr 30, 2032	DP U-976			
		>A> 9522117	Apr 30, 2032	DP U-1939			
BUDESONIDE - UCERIS							
N 203634	001	>A> 9532954	Jun 09, 2020	DP U-1325			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	001	>A> 6123924	Sep 26, 2017	DP		>A> NPP	Jan 27, 2020
		>A> 6123924*PED	Mar 26, 2018			>A> PED	Jul 27, 2020
		>A> 7367333	Nov 11, 2018	DP			
		>A> 7367333*PED	May 11, 2019				
		>A> 7587988	Apr 10, 2026	DP			
		>A> 7587988*PED	Oct 10, 2026				
		>A> 7759328	Jan 29, 2023	DP U-1073			
		>A> 7759328*PED	Jul 29, 2023				
		>A> 7967011	Aug 11, 2021	DP			
		>A> 7967011*PED	Feb 11, 2022				
		>A> 8143239	Jan 29, 2023	DP U-1073			
		>A> 8143239*PED	Jul 29, 2023				
		>A> 8387615	Nov 10, 2024	DP			
		>A> 8387615*PED	May 10, 2025				
		>A> 8575137	Jan 29, 2023	DP U-1073			
		>A> 8575137*PED	Jul 29, 2023				
		>A> 8616196	Apr 07, 2029	DP			
		>A> 8616196*PED	Oct 07, 2029				
		>A> 8875699	Nov 10, 2024	DP			
		>A> 8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	002	>A> 6123924	Sep 26, 2017	DP			
		>A> 6123924*PED	Mar 26, 2018				
		>A> 7367333	Nov 11, 2018	DP			
		>A> 7367333*PED	May 11, 2019				
		>A> 7587988	Apr 10, 2026	DP			
		>A> 7587988*PED	Oct 10, 2026				
		>A> 7759328	Jan 29, 2023	DP U-1073			
		>A> 7759328*PED	Jul 29, 2023				
		>A> 7897646	Sep 09, 2018	U-1118			
		>A> 7897646*PED	Mar 09, 2019				
		>A> 7967011	Aug 11, 2021	DP			
		>A> 7967011*PED	Feb 11, 2022				
		>A> 8143239	Jan 29, 2023	DP U-1073			
		>A> 8143239*PED	Jul 29, 2023				
		>A> 8387615	Nov 10, 2024	DP			
		>A> 8387615*PED	May 10, 2025				
		>A> 8461211	Sep 09, 2018	U-1118			
		>A> 8461211*PED	Mar 09, 2019				
		>A> 8575137	Jan 29, 2023	DP U-1073			
		>A> 8575137*PED	Jul 29, 2023				
		>A> 8616196	Apr 07, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT								
N 021929	002	>A> 8616196*PED	Oct 07, 2029					
		>A> 8875699	Nov 10, 2024		DP			
		>A> 8875699*PED	May 10, 2025					
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	001	>A> 9533046	Dec 26, 2028		DP U-219			
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	002	>A> 9533046	Dec 26, 2028		DP U-219			
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	003	>A> 9533046	Dec 26, 2028		DP U-219			
CARBIDOPA; LEVODOPA - RYTARY								
N 203312	004	>A> 9533046	Dec 26, 2028		DP U-219			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD								
N 203100	001						>A> NPP	Jan 27, 2020
CRISABOROLE - EUCRISA								
N 207695	001	>A> 8039451	Jun 11, 2026	DS	DP			
		>A> 8168614	Jan 20, 2030		U-1932			
		>A> 8501712	Feb 16, 2027		U-1932			
DEOXYCHOLIC ACID - KYBELLA								
N 206333	001	>A> 9522155	Feb 21, 2028		DP U-1940			
DICLOFENAC POTASSIUM - ZIPSOR								
N 022202	001	>A> 9561200	Feb 24, 2029		U-1482			
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	001	>A> 9532971	Jun 01, 2029		DP			
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	002	>A> 9532971	Jun 01, 2029		DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	001	>A> 6446627	Dec 18, 2017		DP		>A> NP	Jan 27, 2020
		>A> 6701917	Jun 23, 2021		DP			
		>A> 6718972	Jun 23, 2021		DP			
		>A> 6748947	Jun 23, 2021		DP			
		>A> 6871646	Jun 23, 2021		DP			
		>A> 7540282	May 06, 2023		DP			
		>A> 8006690	Jun 23, 2021		DP			
		>A> 8651103	Mar 26, 2028		DP			
		>A> 8714149	Feb 25, 2032		DP			
		>A> 8978966	Jan 13, 2032		DP			
		>A> 9216260	Jun 28, 2031		DP			
		>A> 9463288	May 19, 2025		DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	002	>A> 6446627	Dec 18, 2017		DP		>A> NP	Jan 27, 2020
		>A> 6701917	Jun 23, 2021		DP			
		>A> 6718972	Jun 23, 2021		DP			
		>A> 6748947	Jun 23, 2021		DP			
		>A> 6871646	Jun 23, 2021		DP			
		>A> 7540282	May 06, 2023		DP			
		>A> 8006690	Jun 23, 2021		DP			
		>A> 8651103	Mar 26, 2028		DP			
		>A> 8714149	Feb 25, 2032		DP			
		>A> 8978966	Jan 13, 2032		DP			
		>A> 9216260	Jun 28, 2031		DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 002	>A> 9463288	May 19, 2025	DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 003	>A> 6446627	Dec 18, 2017	DP		>A> NP	Jan 27, 2020
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 001	>A> 6446627	Dec 18, 2017	DP		>A> NP	Jan 27, 2020
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9415008	Oct 06, 2034	DP U-645			
	>A> 9463288	May 19, 2025	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 002	>A> 6446627	Dec 18, 2017	DP		>A> NP	Jan 27, 2020
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 003	>A> 6446627	Dec 18, 2017	DP		>A> NP	Jan 27, 2020
	>A> 6701917	Jun 23, 2021	DP			
	>A> 6718972	Jun 23, 2021	DP			
	>A> 6748947	Jun 23, 2021	DP			
	>A> 6871646	Jun 23, 2021	DP			
	>A> 7540282	May 06, 2023	DP			
	>A> 8006690	Jun 23, 2021	DP			
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9066957	Oct 06, 2034	DP U-645			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	001	>A> 9486451	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	002	>A> 9486451	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	003	>A> 9486451	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	004	>A> 9486451	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	005	>A> 9486451	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	006	>A> 9486451	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	001	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	002	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	003	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	004	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	005	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	006	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	007	>A> 9517236	Oct 30, 2021	DP			
		>A> 9545380	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - VANTRELA ER							
N 207975	001	>A> 8445018	Jul 31, 2029	DP			
		>A> 9216176	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER							
N 207975	002	>A> 8445018	Jul 31, 2029	DP			
		>A> 9216176	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER							
N 207975	003	>A> 8445018	Jul 31, 2029	DP			
		>A> 9216176	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER							
N 207975	004	>A> 8445018	Jul 31, 2029	DP			
		>A> 9216176	Sep 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - VANTRELA ER							
N 207975	004	>A> 8445018	Jul 31, 2029	DP			
		>A> 9216176	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER							
N 207975	005	>A> 8445018	Jul 31, 2029	DP			
		>A> 9216176	Sep 13, 2027	DP			
IBRUTINIB - IMBRUVICA							
N 205552	001	>A> 9540382	Aug 18, 2033	U-1456		>A> I-741	Jan 18, 2020
		>A> 9540382	Aug 18, 2033	U-1650		>A> ODE	Jan 18, 2024
		>A> 9540382	Aug 18, 2033	U-1684			
		>A> 9540382	Aug 18, 2033	U-1946			
		>A> 9540382	Aug 18, 2033	U-1947			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081	002	>A> 9561331	Aug 28, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538	001	>A> 9561331	Aug 28, 2024	DP			
INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33							
N 208673	001	>A> 9561331	Aug 28, 2024	DP			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N 021629	003	>A> 9561331	Aug 28, 2024	DP			
LEUPROLIDE ACETATE - ELIGARD							
N 021343	001	>A> 9254307	Oct 28, 2018	DS DP			
LEUPROLIDE ACETATE - ELIGARD							
N 021379	001	>A> 8470359	Oct 15, 2023	DS DP U-621			
		>A> 8486455	Oct 28, 2018	DS DP			
		>A> 8840916	Nov 13, 2020	DP			
		>A> 9539333	Nov 13, 2020	DS DP U-621			
LEUPROLIDE ACETATE - ELIGARD							
N 021488	001	>A> 8470359	Oct 15, 2023	DS DP U-621			
		>A> 8486455	Oct 28, 2018	DS DP			
		>A> 8840916	Nov 13, 2020	DP			
		>A> 9539333	Nov 13, 2020	DS DP U-621			
LEUPROLIDE ACETATE - ELIGARD							
N 021731	001	>A> 8470359	Oct 15, 2023	DS DP U-621			
		>A> 8486455	Oct 28, 2018	DS DP			
		>A> 8840916	Nov 13, 2020	DP			
		>A> 9539333	Nov 13, 2020	DS DP U-621			
LINACLOTIDE - LINZESS							
N 202811	003					>A> NCE	Aug 30, 2017
						>A> NS	Jan 25, 2020
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	001					>A> I-703	Jan 30, 2018
						>A> M-188	Oct 14, 2019
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	002					>A> I-703	Jan 30, 2018
						>A> M-188	Oct 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 003					>A> I-703	Jan 30, 2018
					>A> M-188	Oct 14, 2019
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 004					>A> I-703	Jan 30, 2018
					>A> M-188	Oct 14, 2019
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 005					>A> I-703	Jan 30, 2018
					>A> M-188	Oct 14, 2019
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 006					>A> I-703	Jan 30, 2018
					>A> M-188	Oct 14, 2019
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001					>A> M-195	Jan 27, 2020
					>A> NPP	Jan 27, 2020
					>A> PED	Jul 27, 2020
					>A> PED	Jul 27, 2020
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002					>A> NPP	Jan 27, 2020
					>A> PED	Jul 27, 2020
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003					>A> M-195	Jan 27, 2020
					>A> NPP	Jan 27, 2020
					>A> PED	Jul 27, 2020
					>A> PED	Jul 27, 2020
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 005					>A> M-195	Jan 27, 2020
					>A> NPP	Jan 27, 2020
					>A> PED	Jul 27, 2020
					>A> PED	Jul 27, 2020
MARAVIROC - SELZENTRY						
N 022128 001					>A> NPP	Nov 04, 2019
					>A> NS	Nov 04, 2019
MARAVIROC - SELZENTRY						
N 022128 002					>A> NPP	Nov 04, 2019
					>A> NS	Nov 04, 2019
MARAVIROC - SELZENTRY						
N 022128 003	>A> 6586430	Dec 01, 2019	DS DP U-824		>A> NPP	Nov 04, 2019
	>A> 6667314	Aug 06, 2021	DS DP U-824		>A> NS	Nov 04, 2019
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY						
N 022128 004	>A> 6586430	Dec 01, 2019	DS DP U-824		>A> NPP	Nov 04, 2019
	>A> 6667314	Aug 06, 2021	DS DP U-824		>A> NS	Nov 04, 2019
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY						
N 208984 001					>A> NP	Nov 04, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP							
N 204824 001	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 002	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 003	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 004	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 005	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 006	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 007	>A>	9533102	Jan 24, 2026	DP			
METHOTREXATE - OTREXUP							
N 204824 008	>A>	9533102	Jan 24, 2026	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960 001	>A>	9545399	Aug 14, 2033	DP U-1827			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960 002	>A>	9545399	Aug 14, 2033	DP U-1827			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960 003	>A>	9545399	Aug 14, 2033	DP U-1827			
MORPHINE SULFATE - ARYMO ER							
N 208603 001	>A>	9044402	Jul 01, 2033	DP U-1556			
MORPHINE SULFATE - ARYMO ER							
N 208603 002	>A>	9044402	Jul 01, 2033	DP U-1556			
MORPHINE SULFATE - ARYMO ER							
N 208603 003	>A>	9044402	Jul 01, 2033	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777 001	>A>	9555000	Apr 04, 2023	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777 002	>A>	9555000	Apr 04, 2023	DP U-1556			
NUSINERSEN SODIUM - SPINRAZA							
N 209531 001	>A>	6166197	Dec 26, 2017	DS		>A> ODE	Dec 23, 2023
	>A>	6210892	Oct 07, 2018	U-1942			
	>A>	7101993	Sep 05, 2023	DS			
	>A>	7838657	Jul 11, 2027	DS			
	>A>	8110560	Dec 05, 2025	U-1942			
	>A>	8110560	Dec 05, 2025	U-1943			
	>A>	8110560	Dec 05, 2025	U-1944			
	>A>	8361977	May 27, 2030	DS DP			
	>A>	8980853	Nov 24, 2030	U-1941			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLOPATADINE HYDROCHLORIDE - PAZEO							
N 206276 001	>A> 9533053	May 19, 2032		DP			
OXYCODONE HYDROCHLORIDE - OXAYDO							
N 202080 001	>A> 9492443	May 26, 2024	DS	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO							
N 202080 002	>A> 9492443	May 26, 2024		DP			
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE							
N 208552 001	>A> 7812049	May 02, 2028		U-1959		>A> NP	Jan 18, 2020
	>A> 8420688	Aug 02, 2024		U-1959			
	>A> 8883838	Dec 01, 2031		DP			
PIRFENIDONE - ESBRIET							
N 208780 001						>A> NCE	Oct 16, 2019
						>A> ODE	Oct 15, 2021
PIRFENIDONE - ESBRIET							
N 208780 002						>A> NCE	Oct 16, 2019
						>A> ODE	Oct 15, 2021
PIRFENIDONE - ESBRIET							
N 208780 003						>A> NCE	Oct 16, 2019
						>A> ODE	Oct 15, 2021
PLECANATIDE - TRULANCE							
N 208745 001	>A> 7041786	Mar 25, 2023	DS			>A> NCE	Jan 19, 2022
	>A> 7799897	Jun 09, 2022	DS				
	>A> 8637451	Mar 28, 2022		U-1964			
PREDNISONE - RAYOS							
N 202020 001	>A> 9504699	Aug 03, 2027		U-1362			
PREDNISONE - RAYOS							
N 202020 002	>A> 9504699	Aug 03, 2027		U-1362			
REGADENOSON - LEXISCAN							
N 022161 001						>A> M-194	Jan 17, 2020
RIVAROXABAN - XARELTO							
N 022406 001	>A> 9539218	Feb 17, 2034		U-1953			
	>A> 9539218	Feb 17, 2034		U-1954			
	>A> 9539218	Feb 17, 2034		U-1955			
	>A> 9539218	Feb 17, 2034		U-1956			
	>A> 9539218	Feb 17, 2034		U-1957			
RIVAROXABAN - XARELTO							
N 022406 002	>A> 9539218	Feb 17, 2034		U-1953			
	>A> 9539218	Feb 17, 2034		U-1954			
	>A> 9539218	Feb 17, 2034		U-1955			
	>A> 9539218	Feb 17, 2034		U-1956			
	>A> 9539218	Feb 17, 2034		U-1957			
RIVAROXABAN - XARELTO							
N 022406 003	>A> 9539218	Feb 17, 2034		U-1953			
	>A> 9539218	Feb 17, 2034		U-1954			
	>A> 9539218	Feb 17, 2034		U-1955			
	>A> 9539218	Feb 17, 2034		U-1957			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001					>A> ODE	Dec 19, 2023
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002					>A> ODE	Dec 19, 2023
SACROSIDASE - SUCRAID						
N 020772 001	>A> 9469847	Feb 07, 2034	DS DP			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 001	>A> 7459428	Feb 02, 2019	U-1945			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 002	>A> 7459428	Feb 02, 2019	U-1945			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 003	>A> 7459428	Feb 02, 2019	U-1945			
SODIUM OXYBATE - XYREM						
N 021196 001	>A> 9539330	Dec 22, 2019	DP			
SOFOSBUVIR - SOVALDI						
N 204671 001	>A> 9549941	Mar 26, 2029	U-1958			
TASIMELTEON - HETLIOZ						
N 205677 001	>A> 9539234	Jan 25, 2033	U-1934			
	>A> 9549913	Jan 25, 2033	U-1486			
TAVABOROLE - KERYDIN						
N 204427 001	>A> 9549938	Feb 16, 2026	U-1951			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT						
N 203441 001	>A> 9539310	Nov 01, 2025	U-1320			
	>A> 9545434	Nov 01, 2025	U-1320			
	>A> 9545435	Nov 01, 2025	U-1320			
	>A> 9555079	Nov 01, 2025	U-1320			
THIOTEPA - TEPADINA						
N 208264 001					>A> ODE	Jan 26, 2024
THIOTEPA - TEPADINA						
N 208264 002					>A> ODE	Jan 26, 2024
TICAGRELOR - BRILINTA						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	>A> RE46276	Dec 02, 2019	DS DP U-1935			
	>A> RE46276	Dec 02, 2019	DS DP U-1936			
	>A> RE46276	Dec 02, 2019	DS DP U-1937			
	>A> RE46276	Dec 02, 2019	DS DP U-1938			
TICAGRELOR - BRILINTA						
N 022433 002	>A> 6525060	Dec 02, 2019	DS DP U-1171	Y		
	>A> 6525060	Dec 02, 2019	DS DP U-1860	Y		
	>A> 6525060	Dec 02, 2019	DS DP U-1862	Y		
	>A> 6525060	Dec 02, 2019	DS DP U-1863	Y		
	>A> RE46276	Dec 02, 2019	DS DP U-1935			
	>A> RE46276	Dec 02, 2019	DS DP U-1936			
	>A> RE46276	Dec 02, 2019	DS DP U-1937			
	>A> RE46276	Dec 02, 2019	DS DP U-1938			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TICAGRELOR - BRILINTA							
N 022433 002	>A>	6525060	Dec 02, 2019	DS DP U-1171	Y		
	>A>	6525060	Dec 02, 2019	DS DP U-1860	Y		
	>A>	6525060	Dec 02, 2019	DS DP U-1862	Y		
	>A>	6525060	Dec 02, 2019	DS DP U-1863	Y		
	>A>	RE46276	Dec 02, 2019	DS DP U-1935			
	>A>	RE46276	Dec 02, 2019	DS DP U-1936			
	>A>	RE46276	Dec 02, 2019	DS DP U-1937			
	>A>	RE46276	Dec 02, 2019	DS DP U-1938			
TIOTROPIUM BROMIDE - SPIRIVA							
N 021395 001	>A>	6777423	Sep 24, 2021	DS DP			
	>A>	6777423*PED	Mar 24, 2022				
	>A>	6908928	Sep 24, 2021	DS DP U-566			
	>A>	6908928	Sep 24, 2021	DS DP U-762			
	>A>	6908928*PED	Mar 24, 2022				
	>A>	7070800	Jan 22, 2022	DP U-566			
	>A>	7070800*PED	Jul 22, 2022				
	>A>	7309707	Sep 24, 2021	DS DP			
	>A>	7309707*PED	Mar 24, 2022				
	>A>	7642268	Sep 24, 2021	DS DP			
	>A>	7642268*PED	Mar 24, 2022				
	>A>	7694676	Mar 12, 2027	DP			
	>A>	7694676*PED	Sep 12, 2027				
	>A>	8022082	Jan 19, 2026	DP U-1186			
	>A>	8022082*PED	Jul 19, 2026				
	>A>	RE38912	Oct 11, 2021	DP			
	>A>	RE38912*PED	Apr 11, 2022				
	>A>	RE39820	Jan 30, 2018	DS DP U-566			
	>A>	RE39820*PED	Jul 30, 2018				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 001	>A>	5964416	Oct 04, 2016	DP			
	>A>	5964416*PED	Apr 04, 2017				
	>A>	6149054	Dec 16, 2016	DP			
	>A>	6149054*PED	Jun 16, 2017				
	>A>	6176442*PED	Dec 01, 2016				
	>A>	6453795	Dec 05, 2016	DP			
	>A>	6453795*PED	Jun 05, 2017				
	>A>	6726124	Oct 04, 2016	DP			
	>A>	6726124*PED	Apr 04, 2017				
	>A>	6846413	Aug 28, 2018	DP			
	>A>	6846413*PED	Feb 28, 2019				
	>A>	6977042	Aug 28, 2018	DP			
	>A>	6977042*PED	Feb 28, 2019				
	>A>	6988496	Feb 23, 2020	DP			
	>A>	6988496*PED	Aug 23, 2020				
	>A>	7104470	Oct 04, 2016	DP			
	>A>	7104470*PED	Apr 04, 2017				
	>A>	7246615*PED	Dec 01, 2016				
	>A>	7284474	Aug 26, 2024	DP			
	>A>	7284474*PED	Feb 26, 2025				
	>A>	7396341	Oct 10, 2026	DP			
	>A>	7396341*PED	Apr 10, 2027				
	>A>	7802568	Feb 26, 2019	DP			
	>A>	7802568*PED	Aug 26, 2019				
	>A>	7837235	Mar 13, 2028	DP			
	>A>	7837235*PED	Sep 13, 2028				
	>A>	7896264	May 26, 2025	DP			
	>A>	7896264*PED	Nov 26, 2025				
	>A>	7988001	Aug 04, 2021	DP			
	>A>	7988001*PED	Feb 04, 2022				
	>A>	RE39820	Jan 30, 2018	DS DP U-1593			
	>A>	RE39820*PED	Jul 30, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 002	>A>	6149054	Dec 16, 2016	DP			
	>A>	6846413	Aug 28, 2018	DP			
	>A>	6846413*PED	Feb 28, 2019				
	>A>	6977042	Aug 28, 2018	DP			
	>A>	6977042*PED	Feb 28, 2019				
	>A>	6988496	Feb 23, 2020	DP			
	>A>	6988496*PED	Aug 23, 2020				
	>A>	7284474	Aug 26, 2024	DP			
	>A>	7284474*PED	Feb 26, 2025				
	>A>	7396341	Oct 10, 2026	DP			
	>A>	7396341*PED	Apr 10, 2027				
	>A>	7802568	Feb 26, 2019	DP			
	>A>	7802568*PED	Aug 26, 2019				
	>A>	7837235	Mar 13, 2028	DP			
	>A>	7837235*PED	Sep 13, 2028				
	>A>	7896264	May 26, 2025	DP			
	>A>	7896264*PED	Nov 26, 2025				
	>A>	7988001	Aug 04, 2021	DP			
	>A>	7988001*PED	Feb 04, 2022				
	>A>	8733341	Dec 16, 2029	DP			
	>A>	8733341*PED	Jun 16, 2030				
	>A>	RE39820	Jan 30, 2018	DS DP			
	>A>	RE39820*PED	Jul 30, 2018				
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981 001	>A>	9527833	Jun 17, 2034	DS DP			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981 002	>A>	9527833	Jun 17, 2034	DS DP			
TOPIRAMATE - TROKENDI XR							
N 201635 001	>A>	9549940	Nov 16, 2027	DP		U-1675	
	>A>	9555004	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - TROKENDI XR							
N 201635 002	>A>	9549940	Nov 16, 2027	DP		U-1675	
	>A>	9555004	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - TROKENDI XR							
N 201635 003	>A>	9549940	Nov 16, 2027	DP		U-1675	
	>A>	9555004	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - TROKENDI XR							
N 201635 004	>A>	9549940	Nov 16, 2027	DP		U-1675	
	>A>	9555004	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - QUDEXY XR							
N 205122 001	>A>	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 002	>A>	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 003	>A>	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 004	>A>	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 005	>A>	9555005	Mar 19, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2017

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	>A> 6765117	Oct 24, 2017	DS			
		>A> 7417070	Jul 30, 2026	DS			
		>A> 7544713	Jul 14, 2024			U-1475	
		>A> 8252839	May 24, 2024	DP			
		>A> 8349892	Jan 22, 2031	DP			
		>A> 8410169	Feb 13, 2030	DP			
		>A> 8497393	Dec 15, 2028	DS			
		>A> 8747897	Oct 08, 2029	DP			
		>A> 9050311	May 24, 2024	DS DP			
		>A> 9278901	May 24, 2024			U-1475	
		>A> 9393203	Apr 27, 2026	DP		U-1877	
		>A> 9422223	May 24, 2024	DP			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm